Medulloblastoma is the most common malignant brain tumour of childhood. Although 70% of patients can be cured, the aggressive treatments leave many survivors with significant mental and physical disabilities. Professor Pilkington is developing a new approach to the treating of childhood medulloblastoma that could impact on both survival rates and quality of survival for young patients.

Thank you

This research project on medulloblastoma has been successfully completed. Your donations allow us to fund ground-breaking research that can improve treatments given to children with cancer. Thank you. Your help allows us to continue to find ways to drive up the chances of survival for children with cancer and reduce the toxic side effects that can affect the rest of their lives.

Project Details

  • Project Title

    The genetics of familial leukaemia

  • Lead Researcher

    Professor Geoff Pilkington

  • Research Centre

    University of Portsmouth

  • City & Institution Postcode

    Portsmouth, PO1 2UP

  • Start Date

    1 July 2013

  • Duration

    3 years

  • Grant Amount


20190621 CWC UCL HiRes LoRes011


Medulloblastoma is the most common malignant brain tumour of childhood. Whilst around 70% of affected children can now be cured, this comes at a high cost as the aggressive nature of the treatment leaves survivors with a poor quality of life, often suffering serious physical and mental disabilities. The problem is that this type of tumour is complex and currently both good and bad prognosis patients are grouped together and receive the same aggressive treatment. Using cutting-edge molecular genetic techniques, Professor Pilkington’s team is unravelling the biology of medulloblastoma. They have identified the genetic signalling pathways that underlie development of the disease. Medulloblastomas are known to have an accumulation of a protein called GD3. GD3 is normally involved in cell death but, crucially, in medulloblastoma it is modified in such a way that it does not function normally and thus cannot drive the death of aberrant cells. The team has already shown, in the lab, that reversing this modification results in increased cell death. Their previous gene therapy approach to this work was successful but the gene that was previously used has some associated problems that rendered it unsuitable for progression to clinical trial. They now need to try an alternative approach to take the technique forward to clinical trial.

What difference will this project make?

New treatment approaches for medulloblastoma are desperately needed, not only to improve survival rates but, crucially, to reduce the devastating morbidity associated with current treatments. If successful, the current project will take Professor Pilkington’s new treatment approach a step closer to clinical trial. Ultimately, this approach could impact significantly on both survival and quality of survival for young patients with medulloblastoma. About childhood brain tumours Brain tumour initiative

About the Research Team

Professor Pilkington has worked in neuro-oncology research for more than 40 years. His Cellular and Molecular Neuro-oncology laboratories at the University of Portsmouth represent the flagship centre for dedicated brain tumour research in the south of England. Professor Pilkington has assembled a multi-disciplinary and international research team, with years of experience and each bringing different areas of expertise to the project. Collaborators include Dr Michael Taylor from the Hospital for Sick Children in Toronto, whose laboratory leads the world in medulloblastoma research.
Newsletter icon
Newsletter icon

Sign up to our e-newsletter today

Sign up to our e-newsletter and receive exclusive stories straight to your inbox. You will also find out about our latest childhood cancer research news along with updates on our fundraising events, charity news and opportunities to support us. Don’t miss out!

By signing up to this newsletter I agree to receive general and financial appeal emails from Children with Cancer UK